PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies von Lee, J-m., Ledermann, J.A., Kohn, E.C.

Volltext

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup... von Ruers, T., Punt, C., Van Coevorden, F., Pierie, J.P.E.N., Borel-Rinkes, I., Ledermann, J.A., Poston, G., Bechstein, W., Lentz, M.A., Mauer, M., Van Cutsem, E., Lutz, M.P., Nordlinger, B.

Volltext

A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer von McCormack, M, Kadalayil, L, Hackshaw, A, Hall-Craggs, M A, Symonds, R P, Warwick, V, Simonds, H, Fernando, I, Hammond, M, James, L, Feeney, A, Ledermann, J A

Volltext

PARP inhibitors in ovarian cancer von Ledermann, J A

Volltext

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer von McNeish, I.A., Ledermann, J.A., Webber, L., James, L., Kaye, S.B., Hall, M., Hall, G., Clamp, A., Earl, H., Banerjee, S., Kristeleit, R., Raja, F., Feeney, A., Lawrence, C., Dawson-Athey, L., Persic, M., Khan, I.

Volltext

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data von Raja, F.A., Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M.K., Vergote, I.B., Gonzalez-Martin, A., Alberts, D.S., Plante, M., Torri, V., Ledermann, J.A.

Volltext

Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines von Colombo, N., Ledermann, J.A.

Volltext

Combining conventional therapy with immunotherapy: A risky business? von Coosemans, A., Vankerckhoven, A., Baert, T., Boon, L., Ruts, H., Riva, M., Blagden, S., Delforge, M., Concin, N., Mirza, M.R., Ledermann, J.A., du Bois, A., Vergote, I.

Volltext

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments von Ledermann, J.A., Canevari, S., Thigpen, T.

Volltext

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer von Mirza, M.R., Pignata, S., Ledermann, J.A.

Volltext

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up von Oaknin, A., Bosse, T.J., Creutzberg, C.L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M.R., Ledermann, J.A., Colombo, N.

Volltext

Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in t... von Glynne-Jones, R., Kadalayil, L., Meadows, H.M., Cunningham, D., Samuel, L., Geh, J.I., Lowdell, C., James, R., Beare, S., Begum, R., Ledermann, J.A., Sebag-Montefiore, D.

Volltext

Front-line therapy of advanced ovarian cancer: new approaches von Ledermann, J A

Volltext

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer von Miller, R.E., Leary, A., Scott, C.L., Serra, V., Lord, C.J., Bowtell, D., Chang, D.K., Garsed, D.W., Jonkers, J., Ledermann, J.A., Nik-Zainal, S., Ray-Coquard, I., Shah, S.P., Matias-Guiu, X., Swisher, E.M., Yates, L.R.

Volltext

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Ledermann, J A, Raja, F A, Fotopoulou, C, Gonzalez-Martin, A, Colombo, N, Sessa, C

Volltext

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer von Raja, F A, Griffin, C L, Qian, W, Hirte, H, Parmar, M K, Swart, A M, Ledermann, J A

Volltext

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial von Maughan, TS, James, RD, Kerr, DJ, Ledermann, JA, Seymour, MT, Topham, C, McArdle, C, Cain, D, Stephens, RJ

Volltext

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study von Matulonis, U.A., Shapira-Frommer, R., Santin, A.D., Lisyanskaya, A.S., Pignata, S., Vergote, I., Raspagliesi, F., Sonke, G.S., Birrer, M., Provencher, D.M., Sehouli, J., Colombo, N., González-Martín, A., Oaknin, A., Ottevanger, P.B., Rudaitis, V., Katchar, K., Wu, H., Keefe, S., Ruman, J., Ledermann, J.A.

Volltext

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up von González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R.E., Pothuri, B., Ray-Coquard, I., Tan, D.S.P., Bellet, E., Oaknin, A., Ledermann, J.A.

Volltext

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline von Sessa, C., Balmaña, J., Bober, S.L., Cardoso, M.J., Colombo, N., Curigliano, G., Domchek, S.M., Evans, D.G., Fischerova, D., Harbeck, N., Kuhl, C., Lemley, B., Levy-Lahad, E., Lambertini, M., Ledermann, J.A., Loibl, S., Phillips, K.-A., Paluch-Shimon, S.

Volltext